Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc.'s first-quarter earnings beat expectations, but investors may be paying more attention to the latest information the company is sharing about its plans for aducanumab, the experimental Alzheimer's disease drug that has sent the stock on a wild ride.

Biogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decision

Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 million, or $2.69 per share for the quarter from $1.40 billion, or $8.08 per share, a year earlier.

Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

It's partially because expectations weren't very high in the first place.

Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough

The shares of Biogen Inc (NASDAQ:BIIB) were last seen down 3.9% at $259.23, even after the pharmaceutical concern posted first-quarter earnings of $5.34 per share, which topped analysts' estimates.

Weak Drug Sales Undermine BIIB's Earnings Beat

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Surpasses Q1 Earnings and Revenue Estimates

Shares of Biogen (NASDAQ:BIIB) moved higher by 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 41.58% year over year to $5.34, which beat the estimate of $5.04.

Recap: Biogen Q1 Earnings

Shares of Biogen gained 1.4% in premarket trading on Thursday after the drug maker beat earnings expectations and even though it saw revenue drop 25% for the quarter. Biogen had earnings of $410.2 million, or $2.69 per share, in the first quarter of 2021, compared to $1.4 billion, or $8.10 per share, in the like quarter in 2020.

Biogen's stock is up, though revenue fell 25% for the quarter

Biogen Inc (BIIB.O) beat first-quarter profit estimates on Thursday as higher-than-expected sales for spinal muscular atrophy treatment Spinraza cushioned the blow from eroding sales of its multiple sclerosis drug Tecfidera due to cheaper rivals.

Spinraza outweighs weak multiple sclerosis drug sales, drives Biogen profit beat

NEW YORK, NY / ACCESSWIRE / April 22, 2021 / Biogen, Inc. (SAO:BIIB34) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 22, 2021 at 8:00 AM Eastern Time.

Biogen, Inc. to Host Earnings Call

Biogen (NASDAQ:BIIB) unveils its next round of earnings this Thursday, April 22. Here is Benzinga's everything-that-matters guide for the earnings announcement.

A Preview Of Biogen's Earnings

AstraZeneca

Johnson & Johnson

Moderna

Pfizer

Sarepta Therapeutics

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA® (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. These data are being presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22.

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI® (natalizumab) as well as new real-world experience data from VUMERITY® (diroximel fumarate). The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS.

New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that China's National Medical Products Administration (NMPA) has approved TECFIDERA® (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.1 It has been used to treat more than 500,000 individuals with MS worldwide.1 The approval brings a new treatment option to people in China living with relapsing MS and also continues to expand the company's presence in the country.

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

Citigroup

Comerica

eBay

Intel

Loews

Liberty Global Ltd

Lumen Technologies

Oracle

Regeneron Pharmaceuticals

Seagate Technology Holdings PLC

Synchrony Financial

Cambria Shareholder Yield ETF

AT&T

Wells Fargo

The top net payout yield stocks far outperformed the total return of the S&P 500 during Q1.

Top Net Payout Yields - April 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer's disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting.

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

Sage Therapeutics unveiled promising results for its Biogen-partnered essential tremors treatment known as SAGE-324 on Monday, but Sage stock tripped on worse-than-expected side effects. The post Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug appeared first on Investor's Business Daily.

Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug

SAGE Therapeutics

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule in the pact, cleared a Phase 2 trial for essential tremor (ET), a progressive disorder that causes involuntary muscle movement.

Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out

Gilead Sciences

These six pharmaceutical/biotech stocks have been pegged as the worst performers coming out of the market's COVID lows. Three of the six laggards - Gilead, Biogen, and Regeneron - have a disease area in which they excel with compelling plans for ancillary growth.

On Sale: Glitter From The Healthcare Wreckage, Biotech Edition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study (n=67 full analysis set) achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 upper limb tremor score on Day 2

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

iTeos Therapeutics, Inc.

Novavax

Upcoming events could send these stocks screaming higher or lower.

3 Biotech Stocks With Big Catalysts Around the Corner

Apple

Alibaba

A few months ago, GuruFocus launched the "baskets" feature, which allows users to place stocks in one of four virtual baskets based on their level of interest:

News for Biogen Stock (BIIB)